Mumps

Mumps, a contagious viral disease caused by the mumps virus (MuV), primarily affects the salivary glands, leading to inflammation and swelling. By leveraging our extensive expertise and state-of-the-art facilities, our company is uniquely positioned to support our clients in advancing innovative mumps vaccine and therapeutic solutions.

Introduction to Mumps

Mumps is an infectious disease caused by the mumps virus, a member of the Paramyxoviridae family. Characterized by symptoms such as fever, headache, and parotitis (swelling of the salivary glands), mumps can lead to serious complications, including meningitis, orchitis, and, in rare cases, deafness. Before the introduction of vaccines, mumps was a common childhood disease, often resulting in outbreaks within communities.

Fig.1 Mumps cases in 2017 and ongoing. (Bockelman C., et al., 2018)

Vaccine Development for Mumps

• Monovalent Mumps Vaccines
  The initial development of mumps vaccines focused on monovalent formulations, which target the mumps virus alone. These vaccines were the first line of defense against the disease, providing direct immunity to those vaccinated.
• Measles-Mumps-Rubella (MMR) Vaccines
  The advent of combination vaccines, such as the MMR vaccine, marked a significant milestone. By combining the mumps vaccine with measles and rubella vaccines, public health officials were able to streamline vaccination efforts, increasing coverage rates and reducing the incidence of all three diseases.
• Measles-Mumps-Rubella-Varicella (MMRV) Vaccines
  Further advancements led to the development of the tetravalent MMRV vaccine, which also protects against varicella (chickenpox). This vaccine offers broader protection, particularly in populations where varicella is also a concern.

Table 1 List of mumps vaccine strains and corresponding genotypes. (Almansour I., 2020)

Therapeutics Development for Mumps

Researchers are exploring the potential of antiviral drugs to target the Paramyxovirus and disrupt its replication cycle. Some of the emerging antiviral approaches include:

• Nucleoside Analogs: These compounds can interfere with viral RNA synthesis, inhibiting the virus's ability to replicate.
• Viral Entry Inhibitors: Therapies that block the virus's entry into host cells can prevent the initial stages of infection.
• Interferon-based Therapies: Enhancing the body's natural interferon response can stimulate the immune system to clear the viral infection.

Our Services

Our dedicated team of accomplished scientists and researchers utilizes cutting-edge biotechnological innovations to propel the progress of mumps vaccine and therapeutic development. Through our comprehensive range of services, clients gain access to a wealth of expertise and resources aimed at driving advancements in this critical field.

Vaccine Development

• Live-attenuated Vaccine
• Inactivated Vaccine
• Toxoid Vaccine
• Viral Vector Vaccine
• Virus-like Particles Vaccine
• Protein Subunit Vaccine
• mRNA Vaccine
• DNA Vaccine

Therapeutic Development

• Small Molecule Drug Development Services
• Therapeutic mRNA Development Services
• Therapeutic Antibody Development Services
• Cell Therapy Development Services

Disease Models

• Type I Interferon (IFN) alpha/beta Receptor Knockout Mice (IFN-α/βR−/−) Models
• MuV Infection Wild-type C57BL/6 Mice Models
• MuV Infection Ferrets Models
• MuV Infection Rhesus Macaques Models

Preclinical research is a critical phase in the development of any new vaccine or therapy. Our services in this area include:

• Molecular Characterization: Detailed analysis of the mumps virus to identify potential targets for vaccine and drug development.
• Immunogenicity Studies: Assessing the immune response to candidate vaccines to ensure they can elicit a protective immune response.
• Efficacy Testing: Rigorous testing in controlled laboratory environments to evaluate the efficacy of new vaccines and therapies before they proceed to clinical trials.

If you are interested in our services, please feel free to contact us.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.